ERBB2 and gastric cancer: After examining the association of MSI/MSS-sig level with clinical outcomes, we observed a better prognosis in MSI-sig high GC patients in XELOX + HER2 subcohort (log rank test, P < 0.05), but not in XELOX subcohort (Supplementary Fig. 5d and Fig. 4a).